Track topics on Twitter Track topics that are important to you
The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Dry Eye Syndrome
0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, Placebo Comparator: Vehicle, 1% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension AM, 2% BOL-303242-X ophthalmic suspension PM
Not yet recruiting
Bausch & Lomb, Inc.
Published on BioPortfolio: 2010-07-15T17:00:00-0400
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X ophthalmic suspension, for the treatment of inflammation followi...
The purpose of this study is to evaluate if DE-101 ophthalmic suspension will safely and effectively improve signs and or symptoms of dry eye disease.
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were ra...
Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes
This is a randomized, double blind, two-arm, parallel group, active controlled bioequivalence study, at multiple clinical trial sites designed to demonstrate bioequivalence of Brinzolamide...
The purpose of this study is to evaluate safety and efficacy of OPC-12759 ophthalmic suspension during 52 weeks in dry eye patients
To analyze the upper eyelid contour of patients with unilateral congenital ptosis who underwent single-strip frontalis suspension.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID), currently only available as 0.1% ophthalmic suspension (Nevanac®). This study utilized hydroxypropyl-β-cyclodextrin (HPBCD) to increase th...
To study the ophthalmic manifestations of patients with allergic fungal sinusitis (AFS) and evaluate the importance of early diagnosis and management in preventing the possible future complications of...
To investigate the effect of nepafenac 0.3% in a once daily dosage regarding pain and healing after photorefractive keratectomy (PRK).
A sensory branch of the trigeminal (5th cranial) nerve. The ophthalmic nerve carries general afferents from the superficial division of the face including the eyeball, conjunctiva, upper eyelid, upper nose, nasal mucosa, and scalp.
Application of pharmaceutically active agents on the tissues of the EYE.
A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility.
One of the MUSCARINIC ANTAGONISTS with pharmacologic action similar to ATROPINE and used mainly as an ophthalmic parasympatholytic or mydriatic.
Persons academically trained to care for patients with eye diseases or structural defects of the eye, under the supervision of an ophthalmologist.